GlassScriptPhysician profile
Veronica O Sarvi
NPI 1801476676
$3,034.34
in general payments reported to CMS, 2019-2025
20 companies · $939 in 2025
The $939 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $888 · 2023: $600 · 2024: $607 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,981 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125 · Education: $39.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,981.39 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $124.98 |
| Education | $39.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $596.76 | 2022-2025 | |
| Abc Home Medical Supply, INC. | $361.15 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $302.65 | 2022-2025 | |
| Boston Scientific Corporation | $288.69 | 2022-2025 | General - Erectile Dysfunction, Rezum Generator, Spaceoar Vue System - 10ml |
| Sumitomo Pharma America, INC. | $269.04 | 2024-2025 | Gemtesa, Orgovyx |
| Abbvie INC. | $257.93 | 2022-2025 | |
| Astellas Pharma US INC | $165.61 | 2022-2025 | Xtandi, Padcev, Myrbetriq |
| Axonics, INC. | $122.19 | 2022-2024 | Axonics |
| Teleflex LLC | $119.75 | 2022 | |
| Endo Pharmaceuticals INC. | $95.30 | 2022-2023 | Aveed, Xiaflex |
| Baxter Healthcare | $87.19 | 2022-2023 | Tisseel |
| Tolmar, INC. | $63.67 | 2025 | Jatenzo, Eligard |
| Antares Pharma, INC. | $58.32 | 2022-2025 | Xyosted |
| Urogen Pharma, INC. | $58.30 | 2022-2025 | |
| 180 Medical, INC. | $53.61 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $47.53 | 2025 | Erleada |
| Progenics Pharmaceuticals, INC. | $29.57 | 2023 | Pylarify |
| Urovant Sciences INC | $21.18 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.11 | 2025 | |
| Dendreon Pharmaceuticals LLC | $16.79 | 2025 | Provenge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Sarvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.